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LETTER
No evidence for a superior platform to develop
therapeutic antibodies rapidly in response to
MERS-CoV and other emerging viruses
Pascal et al. (1) generated mAbs using a plat-
form called VelocImmune and evaluated
their potency against the Middle East respi-
ratory syndrome coronavirus (MERS-CoV)
in vitro side by side with mAbs previously
reported and in a mouse model developed
by using VelociGene technology. The authors
concluded that “Traditional approaches for
development of antibodies are poorly suited
to combating the emergence of novel patho-
gens. . .and that this study forms the basis for
a rapid response to address the public threat
resulting from emerging coronaviruses or
other pathogens that pose a serious threat
to human health in the future.”
To support the superiority of their ap-
proach, as implied by this statement, the
authors cited human mAbs previously pub-
lished by three groups (2–4) and compared
some of them with their own REGN3051 and
REGN3048, which they found to be “more
effective neutralizers than previously isolated
MERS-CoV monoclonal antibodies.” They
also report that their antibodies “are >1 log
better inhibitors compared with other pub-
lished antibodies developed with conven-
tional approaches.” However, they did not
evaluate the exceptionally potent (picomolar
IC50) mAbs from one group (2) and used
only published sequences, but not mAbs,
provided by the investigators from the other
groups (3, 4). Thus, effects that could affect
potency, including those resulting from
posttranslational modifications, are ex-
cluded. They also claim that the VelocIm-
mune platform can rapidly (“within several
weeks”) identify potent mAbs. However,
using phage display for panning of a very
large human antibody library, Ying et al.
(2) identified the exceptionally potent
mAb m336 in a week.
According to the authors, their mouse
model of MERS-CoV infection was established
by replacing the mouse gene encoding a
receptor targeted by the virus (DPP4) with
its human counterpart, such that “this hu-
manized DPP4 in vivo model of MERS-
CoV infection recapitulates pathological
sequelae that are seen in MERS-CoV in-
fection of humans.” To our knowledge,
currently, there is no animal model that
can recapitulate pathology of human MERS-
CoV infections in humans; therefore, it fol-
lows from this statement that their model
is superior to others, which is not based on
evidence. Because a full understanding of
MERS pathogenesis and pathology in hu-
mans is uncertain, claiming that their
model recapitulates pathological sequelae
in humans, especially in the absence of
morbidity and mortality, seems premature
and unjustifiable. Moreover, a marmoset
model (5) may be the most relevant model
of MERS-CoV infection and disease. It is
not cited in the text, although the reference
for it is given in the bibliography.
Finally, in the title of the article, the
authors claim that their antibodies are fully
human. However, only the germ-line anti-
bodies inserted in the mouse genome are
fully human. Because the maturation of
those antibodies is in mice and the toler-
ance checkpoints are by mouse proteins in
a mouse environment, the somatic muta-
tions could lead to cross-reactivity of their
antibodies with human tissues and immu-
nogenicity, and therefore to undesirable
adverse events and safety concerns.
Taken together, the data do not provide
evidence that their platform of developing
mAbs, as well as models of infection and
disease, is superior.
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